Alexion wins priority review for Ultomiris' aHUS indication; FDA expands approval of Vertex's Symdeko
→ Alexion $ALXN has scored a speedy review for Ultomiris for patients with atypical hemolytic uremic syndrome (aHUS) after posting positive data from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
